Figure 4.

miR-543 targeted UBE2T in breast cancer cells. (a) The binding sites between miR-543 and UBE2T were predicted by TargetScan. (b) Dual-luciferase reporter assay was conducted to confirm the relationship between miR-543 and UBE2T. **P < 0.001 versus miR-NC group. NC: negative control. WT: wild type, MUT: mutation. (c) Expression level of UBE2T in breast cancer tissues and normal tissues by qRT-PCR. **P < 0.001. n = 36. (d) Pearson’s correlation analysis was used to determine the relationship between expression of miR-543 and UBE2T in breast cancer tissues. (e) RNA pull-down assay was carried out to quantify the UEB2T enrichment in MDA-MB-231 and MCF-7 transfected with bio-miR-543 or bio-miR-NC. Bio-miR-543: Biotin-labeled miR-543. Bio-NC: Biotin-labeled negative control. **P < 0.001 versus bio-NC group. (f) The expression level of UBE2T in MDA-MB-231 and MCF-7 transfected with miR-543 mimic or inhibitor was detected by Western blot, **P < 0.001 versus mimic-NC group. **P < 0.001 versus inhibitor-NC group